Clinical Trial Update: Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab in combination with olaparib and paclitaxel for advanced gastric cancer; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Do-Youn Oh | Conditions: Advanced Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING